PUBLICATIONS
EDITORIALS / COMMENTS
Locoregional versus systemic therapy - robust positive data remain elusive

Sanduzzi-Zamparelli M, 
Bruix J

Nat Rev Clin Oncol. DOI: 10.1038/s41571-018-0047-6;
Pubmed abstract

Assessment of treatment efficacy in hepatocellular carcinoma: response rate, delay in progression or none of them Bruix J, Reig M, Sangro B

Journal of Hepatology 2017;doi: 10.1016/j.jhep.2017.02.032
Pubmed abstract

Pattern of tumor progression in liver cancer: The missing partner in trial design. Reig M, Bruix J. Hepatology. 2015;Sep;:62(3):674-6. doi: 10.1002/hep.27881.
Pubmed abstract

Surgical resection for hepatocellular carcinoma: Moving from what can be done to what is worth doing. Romagnoli R, Mazzaferro V, Bruix J. Hepatology. 2015;Aug;:62(2):340-2. doi: 10.1002/hep.27831.
Pubmed abstract

Does ramucirumab deserve a second chance for liver cancer? Forner A, Reig M. Lancet Oncol. 2015;Jul;:16(7):751-2. doi: 10.1016/S1470-2045(15)00053-4.
Pubmed abstract

Hepatocellular carcinoma surveillance with miRNAs. Forner A. Lancet Oncol. 2015;Jul;:16(7):743-5. doi: 10.1016/S1470-2045(15)00014-5.
Pubmed abstract

Hepatocellular carcinoma: paving the road for further developments. Bruix J. Semin Liver Dis. 2014;Nov:34(4):361.
Pubmed abstract

Hepatocellular carcinoma: current state of the art in diagnosis and treatment. Bruix J, Colombo M. Best Pract Res Clin Gastroenterol. 2014;Oct:28(5):751.
Pubmed abstract

Liver cancer: time to evolve trial design after everolimus failure. Llovet JM. Nat Rev Clin Oncol. 2014;Sep:11(9):506-7.
Pubmed abstract

TERT promoter mutations: gatekeeper and driver of hepatocellular carcinoma. Pinyol R, Tovar V, Llovet JM. J Hepatol. 2014;Sep:61(3):685-7.
Pubmed abstract

FOLFOX-4 vs. doxorubicin for hepatocellular carcinoma: could a negative result be accepted as positive? Liccioni A, Reig M, Bruix J J Hepatol. 2014; Jul:61(1):164-5.
Pubmed abstract

Focal gains of VEGFA: candidate predictors of sorafenib response in hepatocellular carcinoma. Llovet JM Cancer Cell. 2014;May 12:25(5):560-2.
Pubmed abstract

Hepatocellular carcinoma: reasons for phase III failure and novel perspectives on trial design. Llovet JM, Hernandez-Gea V. Clin Cancer Res. 2014;Apr 15:20(8):2072-9.
Pubmed abstract

Liver cancer in 2013: Mutational landscape of HCC-the end of the beginning.

Villanueva A, Llovet JM.

Nat Rev Clin Oncol. 2014;Feb;:11(2):73-4.
Pubmed abstract

Are alpha-fetoprotein and other markers useful in the diagnosis and prognosis of hepatocellular carcinoma?

Forner A, Liccioni A, Reig ME.

Gastroenterol Hepatol. 2014;Jan;:37(1):17-20.
Pubmed abstract

If portal hypertension predicts outcome in cirrhosis, why should this not be the case after surgical resection?

Reig M, Berzigotti A, Bruix J.

Liver Int. 2013;Nov;:33(10):1454-6.
Pubmed abstract

Treatment of hepatocellular carcinoma with radioembolization: gathering assumptions for trial design. Reig M, Burrel M, Bruix J. .J Vasc Interv Radiol. 2013;Aug
Pubmed abstract

Oncolytic immunotherapeutic virus in HCC: Can it compete with molecular therapies? Hernandez-Gea V, Alsinet C, Llovet JM Hepatology 2013;May 11
Pubmed abstract

Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma. Hernandez-Gea V, Toffanin S, Friedman SL, Llovet JM. Gastroenterology 2013;Mar
Pubmed abstract

Management of small hepatocellular carcinoma in cirrhosis: Focus on portal hypertension. Hernandez-Gea V, Turon F, Berzigotti A, Villanueva A. World Journal of Gastroenterology 2013;Feb 28
Pubmed abstract

Intrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapies Sia D, Tovar V, Moeini A, Llovet JM. Oncogene 2013;Jan 14
Pubmed abstract

Sex bias occurrence of hepatocellular carcinoma in Poly7 molecular subclass is associated with EGFR. Keng VW, Sia D, Sarver AL, Tschida BR, Fan D, Alsinet C, Solé M, Lee WL, Kuka TP, Moriarity BS, Villanueva A, Dupuy AJ, Riordan JD, Bell JB, Silverstein KA, Llovet JM, Largaespada DA. Hepatology 2013;Jan
Pubmed abstract

Screening for hepatocellular carcinoma: The rationale for the American Association for the Study of Liver Diseases recommendations. Sherman M, Bruix J, Porayko M, Tran T; for the AASLD Practice Guidelines Committee. Hepatology 2012 Sep;56(3):793-796.
Pubmed abstract

Biomarkers for early diagnosis of hepatocellular carcinoma. Forner A, Bruix J. Lancet Oncology 2012;13:750-751.
Pubmed abstract

Chemoembolization for intermediate HCC: is there proof of survival benefit?. Forner A, Llovet JM, Bruix J. Hepatology 2012;56:984-986
Pubmed abstract

Impact of intra-individual molecular heterogeneity in personalized treatment of hepatocellular carcinoma. Villanueva A, Llovet JM. Hepatology 2012;Dec
Pubmed abstract

HCC is promoted by bacterial translocation and TLR-4 signaling: a new paradigm for chemoprevention and management. Toffanin S, Cornella H, Harrington A, Llovet JM. Hepatology 2012;Nov
Pubmed abstract

Next-generation sequencing: path for driver discovery in hepatocellular carcinoma. Toffanin S, Cornella H, Harrington A, Llovet JM. Gastroenterology 2012;Nov
Pubmed abstract

microRNAs: new ways to block tumor angiogenesis? Toffanin S, Sia D, Villanueva A. J Hepatol. 2012;Sep
Pubmed abstract

Screening for liver cancer: the rush to judgment.

Sherman M, Bruix J.

Ann Intern Med. 2012;Aug 21;:157(4):300-1;
Pubmed abstract

Why men are at higher risk for hepatocellular carcinoma? Keng VW, Largaespada DA, Villanueva A J Hepatol 2012;Aug
Pubmed abstract

Molecular epidemiology in HCV-related hepatocellular carcinoma: first steps. Villanueva A, Forns X, Llovet JM. J Hepatol. 2012;Jul
Pubmed abstract

Cell population genetics and deep sequencing: a novel approach for drivers discovery in hepatocellular carcinoma. Alsinet C, Villanueva A, Llovet JM. J Hepatol. 2012;May
Pubmed abstract

Second-line therapies in hepatocellular carcinoma: emergence of resistance to sorafenib. Villanueva A, Llovet JM. Clin Cancer Res. 2012;Apr 1
Pubmed abstract

Management of hepatocellular carcinoma: an udate. J Bruix, M Sherman. Hepatology 2011;53:1020-1022.
Pubmed abstract

Non-invasive diagnostic criteria for hepatocellular carcinoma: the value of contrast washout at imaging and the death of alpha-fetoprotein. Forner A, Raoul JL. Liver Int. 2011;Nov
Pubmed abstract

Liver cancer: Still a long way to go. J Bruix. Hepatology 2011;5:1-2
Pubmed abstract

The search for an effective partner for sorafenib: the failure of Doxorubicin. M Reig, J Bruix. Gastroenterology 2011;140:1686-1688.
Pubmed abstract

Diagnosis of early hepatocellular carcinoma: ideal goal, but not yet there. S Tremosini, J Bruix. Gastroenterology 2011;140:358-360
Pubmed abstract

Hepatocellular carcinoma enters the sequencing era. Villanueva A, Hoshida Y, Llovet JM. Gastroenterology 2011;Nov
Pubmed abstract

Smoking, hepatitis B virus infection, and development of hepatocellular carcinoma. Sherman M, Llovet JM. J Natl Cancer Inst 2011;Nov 16
Pubmed abstract

Depicting the role of TP53 in hepatocellular carcinoma progression. Villanueva A, Hoshida Y. J Hepatol. 2011;Sep
Pubmed abstract

microRNAs and the MYC network: a major piece in the puzzle of liver cancer. Toffanin S, Alsinet C, Cornella H, Sia D, Llovet JM. Gastroenterology 2011;Jun
Pubmed abstract

Imaging diagnosis of hepatocellular carcinoma. Addendum to hepatocellular carcinoma: diagnosis, staging and treatment strategies. Vilana R, Forner A, García A, Ayuso C, Bru C. Radiología 2011;Mar-Apr
Pubmed abstract

Genomic prognostic markers in hepatocellular carcinoma. Alsinet C, Villanueva A. Gastroenterol Hepatol. 2011;Feb
Pubmed abstract